论文部分内容阅读
目的观察比较替吉奥联合顺铂与多西他赛联合顺铂治疗晚期食管癌的临床效果。方法将92例医院收治的晚期食管癌患者随机分为对照组和观察组,每组46例。对照组采用替吉奥联合顺铂治疗,观察组采用多西他赛联合顺铂治疗,将2组患者的近期疗效、生存率与不良反应发生率进行比较。结果观察组总有效率为78.26%,对照组总有效率为71.74%;观察组不良反应总发生率为34.78%,对照组不良反应总发生率为41.30%;观察组生存率为65.22%,对照组生存率为60.87%,差异均无统计学意义(P>0.05)。结论替吉奥联合顺铂与多西他赛联合顺铂在治疗晚期食管癌方面均有较明显的效果,2种治疗方案在近期治疗效果、生存率及不良反应发生率上不存在显著差异,均能够对晚期食管癌患者进行有效治疗,具有临床推广应用价值。
Objective To compare the clinical efficacy of tegaserod combined with cisplatin and docetaxel combined with cisplatin in the treatment of advanced esophageal cancer. Methods 92 patients with advanced esophageal cancer admitted to the hospital were randomly divided into control group and observation group, 46 cases in each group. The control group was treated with ticlopidine combined with cisplatin. The observation group was treated with docetaxel combined with cisplatin. The short-term efficacy, survival rate and incidence of adverse reactions in the two groups were compared. Results The total effective rate was 78.26% in the observation group, 71.74% in the control group, 34.78% in the observation group, 41.30% in the control group and 65.22% in the observation group Group survival rate was 60.87%, the difference was not statistically significant (P> 0.05). CONCLUSION: The combination of cisplatin and docetaxel plus cisplatin in the treatment of advanced esophageal cancer has obvious effect. There is no significant difference between the two treatment regimens in terms of short-term treatment effect, survival rate and incidence of adverse reactions. All patients with advanced esophageal cancer can be effectively treated with clinical application value.